ASX - By Stock
|
KZA |
Re:
Option 2 vs 3
|
|
rroodd
|
71 |
18K |
2 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
71
|
18K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Option 2 vs 3
|
|
rroodd
|
71 |
18K |
1 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
71
|
18K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Reinstatement to Official Quotation
|
|
rroodd
|
1 |
568 |
1 |
11/10/23 |
11/10/23 |
ASX - By Stock
|
1
|
568
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Trading Halt
|
|
rroodd
|
30 |
9.6K |
5 |
10/10/23 |
10/10/23 |
ASX - By Stock
|
30
|
9.6K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Trading Halt
|
|
rroodd
|
30 |
9.6K |
2 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
30
|
9.6K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Latest CRO-67 data shows success in reducing cancer growth
|
|
rroodd
|
7 |
3.0K |
0 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
7
|
3.0K
|
0
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Acceptance of late-breaking abstract of PNOC022 data
|
|
rroodd
|
7 |
2.2K |
7 |
29/09/23 |
29/09/23 |
ASX - By Stock
|
7
|
2.2K
|
7
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Latest CRO-67 data shows success in reducing cancer growth
|
|
rroodd
|
7 |
3.0K |
3 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
7
|
3.0K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
KZA Media Thread
|
|
rroodd
|
2.0K |
618K |
3 |
19/09/23 |
19/09/23 |
ASX - By Stock
|
2.0K
|
618K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Change in substantial holding
|
|
rroodd
|
1 |
676 |
1 |
11/09/23 |
11/09/23 |
ASX - By Stock
|
1
|
676
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: 2023 Corporate Governance Statement
|
|
rroodd
|
22 |
6.3K |
2 |
01/09/23 |
01/09/23 |
ASX - By Stock
|
22
|
6.3K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: 2023 Corporate Governance Statement
|
|
rroodd
|
22 |
6.3K |
5 |
31/08/23 |
31/08/23 |
ASX - By Stock
|
22
|
6.3K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
Ann: 2023 Corporate Governance Statement
|
|
rroodd
|
22 |
6.3K |
1 |
31/08/23 |
31/08/23 |
ASX - By Stock
|
22
|
6.3K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: 2023 Corporate Governance Statement
|
|
rroodd
|
22 |
6.3K |
4 |
31/08/23 |
31/08/23 |
ASX - By Stock
|
22
|
6.3K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Examples of Suspicious Pricing Action
|
|
rroodd
|
273 |
88K |
2 |
30/08/23 |
30/08/23 |
ASX - By Stock
|
273
|
88K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
DIPG Panel Discussion
|
|
rroodd
|
103 |
38K |
4 |
29/08/23 |
29/08/23 |
ASX - By Stock
|
103
|
38K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
DIPG Panel Discussion
|
|
rroodd
|
103 |
38K |
1 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
103
|
38K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
DIPG Panel Discussion
|
|
rroodd
|
103 |
38K |
1 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
103
|
38K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia announces change to Board of Directors
|
|
rroodd
|
20 |
6.5K |
4 |
11/08/23 |
11/08/23 |
ASX - By Stock
|
20
|
6.5K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
News: KZA Kazia Therapeutics Says Resignation Of Iain Ross As Chairman
|
|
rroodd
|
1 |
415 |
3 |
11/08/23 |
11/08/23 |
ASX - By Stock
|
1
|
415
|
3
|
|
ASX - By Stock
|
KZA |
Re:
top 20
|
|
rroodd
|
27 |
10K |
3 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
27
|
10K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
top 20
|
|
rroodd
|
27 |
10K |
2 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
27
|
10K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Notification regarding unquoted securities - KZA
|
|
rroodd
|
20 |
4.9K |
4 |
25/07/23 |
25/07/23 |
ASX - By Stock
|
20
|
4.9K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Notification regarding unquoted securities - KZA
|
|
rroodd
|
20 |
4.9K |
2 |
25/07/23 |
25/07/23 |
ASX - By Stock
|
20
|
4.9K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Notification regarding unquoted securities - KZA
|
|
rroodd
|
20 |
4.9K |
2 |
23/07/23 |
23/07/23 |
ASX - By Stock
|
20
|
4.9K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Paxalisib receives Fast Track Designation from US FDA
|
|
rroodd
|
42 |
12K |
7 |
09/07/23 |
09/07/23 |
ASX - By Stock
|
42
|
12K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Paxalisib receives Fast Track Designation from US FDA
|
|
rroodd
|
42 |
12K |
3 |
07/07/23 |
07/07/23 |
ASX - By Stock
|
42
|
12K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Paxalisib receives Fast Track Designation from US FDA
|
|
rroodd
|
42 |
12K |
4 |
07/07/23 |
07/07/23 |
ASX - By Stock
|
42
|
12K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
News: KZA Kazia's Paxalisib Receives Fast Track Designation From FDA For Treatment Of Solid Tumor...
|
|
rroodd
|
14 |
4.3K |
2 |
07/07/23 |
07/07/23 |
ASX - By Stock
|
14
|
4.3K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
News: KZA Kazia's Paxalisib Receives Fast Track Designation From FDA For Treatment Of Solid Tumor...
|
|
rroodd
|
14 |
4.3K |
3 |
07/07/23 |
07/07/23 |
ASX - By Stock
|
14
|
4.3K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
News: KZA Kazia's Paxalisib Receives Fast Track Designation From FDA For Treatment Of Solid Tumor...
|
|
rroodd
|
14 |
4.3K |
4 |
07/07/23 |
07/07/23 |
ASX - By Stock
|
14
|
4.3K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
DIPG Panel Discussion
|
|
rroodd
|
103 |
38K |
3 |
06/07/23 |
06/07/23 |
ASX - By Stock
|
103
|
38K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia Corporate Update and Corporate Presentation
|
|
rroodd
|
27 |
7.7K |
3 |
30/06/23 |
30/06/23 |
ASX - By Stock
|
27
|
7.7K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia Corporate Update and Corporate Presentation
|
|
rroodd
|
27 |
7.7K |
7 |
26/06/23 |
26/06/23 |
ASX - By Stock
|
27
|
7.7K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Launch of LUMOS2 Study
|
|
rroodd
|
23 |
6.8K |
1 |
15/06/23 |
15/06/23 |
ASX - By Stock
|
23
|
6.8K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: IONIC Trial Abstract Published at ASCO
|
|
rroodd
|
40 |
14K |
0 |
08/06/23 |
08/06/23 |
ASX - By Stock
|
40
|
14K
|
0
|
|
ASX - By Stock
|
KZA |
Re:
High Quality Research-Non Cancer Disease
|
|
rroodd
|
34 |
11K |
0 |
06/06/23 |
06/06/23 |
ASX - By Stock
|
34
|
11K
|
0
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Executive Leadership changes - Dr John Friend appointed CEO
|
|
rroodd
|
55 |
17K |
2 |
08/05/23 |
08/05/23 |
ASX - By Stock
|
55
|
17K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Executive Leadership changes - Dr John Friend appointed CEO
|
|
rroodd
|
55 |
17K |
2 |
08/05/23 |
08/05/23 |
ASX - By Stock
|
55
|
17K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Executive Leadership changes - Dr John Friend appointed CEO
|
|
rroodd
|
55 |
17K |
2 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
55
|
17K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Executive Leadership changes - Dr John Friend appointed CEO
|
|
rroodd
|
55 |
17K |
1 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
55
|
17K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Executive Leadership changes - Dr John Friend appointed CEO
|
|
rroodd
|
55 |
17K |
1 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
55
|
17K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Executive Leadership changes - Dr John Friend appointed CEO
|
|
rroodd
|
55 |
17K |
3 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
55
|
17K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: March 2023 Quarterly Activities Report and Appendix 4C
|
|
rroodd
|
26 |
8.5K |
1 |
24/04/23 |
24/04/23 |
ASX - By Stock
|
26
|
8.5K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Change of Director's Interest Notices
|
|
rroodd
|
5 |
1.7K |
1 |
06/03/23 |
06/03/23 |
ASX - By Stock
|
5
|
1.7K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia Share Purchase Plan
|
|
rroodd
|
31 |
9.3K |
2 |
23/02/23 |
23/02/23 |
ASX - By Stock
|
31
|
9.3K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Change in substantial holding
|
|
rroodd
|
13 |
5.0K |
4 |
20/01/23 |
20/01/23 |
ASX - By Stock
|
13
|
5.0K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Change in substantial holding
|
|
rroodd
|
13 |
5.0K |
3 |
19/01/23 |
19/01/23 |
ASX - By Stock
|
13
|
5.0K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia raises $4.5m and launches share purchase plan
|
|
rroodd
|
32 |
11K |
3 |
16/01/23 |
16/01/23 |
ASX - By Stock
|
32
|
11K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia raises $4.5m and launches share purchase plan
|
|
rroodd
|
32 |
11K |
4 |
16/01/23 |
16/01/23 |
ASX - By Stock
|
32
|
11K
|
4
|
|